Sutro Biopharma, Inc.
STRO
$0.9026
-$0.3974-30.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -86.98% | -49.66% | 146.89% | 2.64% | 1,217.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -86.98% | -49.66% | 146.89% | 2.64% | 1,217.44% |
| Cost of Revenue | -46.74% | 36.00% | 49.12% | 44.36% | -366.21% |
| Gross Profit | -19.79% | -86.43% | -16.47% | -64.15% | 762.40% |
| SG&A Expenses | -46.26% | -6.14% | -17.52% | -17.99% | 14.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.46% | 25.44% | 31.45% | 26.75% | 21.98% |
| Operating Income | -251.23% | -54.31% | -5.43% | -33.98% | 187.67% |
| Income Before Tax | -249.53% | -2.83% | -25.11% | -17.23% | 235.49% |
| Income Tax Expenses | -85.10% | -- | -94.70% | -- | -- |
| Earnings from Continuing Operations | -333.20% | 1.01% | -24.64% | -16.31% | 189.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -333.20% | 1.01% | -24.64% | -16.31% | 189.80% |
| EBIT | -251.23% | -54.31% | -5.43% | -33.98% | 187.67% |
| EBITDA | -241.23% | -56.40% | -5.51% | -34.98% | 194.11% |
| EPS Basic | -272.33% | 26.89% | 7.41% | -11.13% | 184.08% |
| Normalized Basic EPS | -232.86% | -11.22% | 15.98% | -38.60% | 172.27% |
| EPS Diluted | -272.33% | 26.89% | 7.41% | -11.13% | 184.08% |
| Normalized Diluted EPS | -232.86% | -11.22% | 15.98% | -38.60% | 172.27% |
| Average Basic Shares Outstanding | 35.33% | 35.39% | 34.61% | 4.66% | 6.80% |
| Average Diluted Shares Outstanding | 35.33% | 35.39% | 34.61% | 4.66% | 6.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |